Ensysce Biosciences receives Nasdaq deficiency notice for bid price below $1

Ensysce Biosciences, Inc.

Received Nasdaq deficiency letter on Feb 25, 2026; bid price closed below $1 for 30 consecutive business days.
Company has 180 days, until August 24, 2026, to regain compliance by closing at $1 for 10 consecutive days.
If not compliant by Aug 24, Nasdaq may grant a second 180-day period if other listing standards met.
Company intends to monitor bid price and evaluate options; trading on Nasdaq continues under ENSC.
Failure to regain compliance could lead to delisting, impairing capital raising and market liquidity.

item 3.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-26-008343
form_type: 8-K
ticker: ENSC
cik: 0001716947
company_name: Ensysce Biosciences, Inc.
filed_at: 2026-02-27T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.988088+00:00
generated_at: 2026-05-15T23:06:56.646464+00:00
sec_items: ["3.01"]
event_type: regulatory
sentiment: negative
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-26-008343
json_url: https://secwatch.observer/filing/0001493152-26-008343.json
markdown_url: https://secwatch.observer/filing/0001493152-26-008343.md
text_url: https://secwatch.observer/filing/0001493152-26-008343.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315226008343/0001493152-26-008343-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315226008343/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-26-008343

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.